Prediction of CYP2D6 drug interactions from in vitro data: Evidence for substrate-dependent inhibition

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 47-53

  VandenBrink, Brooke M ^a   Foti, Robert S ^a   Rock, Dan A ^a   Wienkers, Larry C ^a   Wahlstrom, Jan L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMIODARONE; BUFURALOL; CIMETIDINE; CLOZAPINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE; GLUTAMIC ACID; HARMINE; METOPROLOL; PAROXETINE; PROPAFENONE; QUINIDINE; QUININE; SERTRALINE; THIORIDAZINE; TRAMADOL; VERAPAMIL; YOHIMBINE;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

BINDING SITES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FORECASTING; HUMANS; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 84455163212     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041210     Document Type: Article

References (44)

1. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, and Burger DM (2005) Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78:664-674. (Pubitemid 41773642)
2. Abdul Manap R, Wright CE, Gregory A, Rostami-Hodjegan A, Meller ST, Kelm GR, Lennard MS, Tucker GT, and Morice AH (1999) The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol 48:382-387. (Pubitemid 29417722)
3. Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, and Smith RL (1991) Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 3:14-18.
4. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, and Brøsen K (1998) The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 54:261-264. (Pubitemid 28288300)
5. Brøsen K and Gram LF (1989) Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 37:155-160. (Pubitemid 19215455)
6. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518. (Pubitemid 41532451)
7. de Graaf C, Oostenbrink C, Keizers PH, van Vugt-Lussenburg BM, van Waterschoot RA, Tschirret-Guth RA, Commandeur JN, and Vermeulen NP (2007) Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr Drug Metab 8:59-77. (Pubitemid 46043892)
8. Flanagan JU, Maréchal JD, Ward R, Kemp CA, McLaughlin LA, Sutcliffe MJ, Roberts GC, Paine MJ, and Wolf CR (2004) Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J 380:353-360. (Pubitemid 38788106)
9. Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981-987.
10. Foti RS and Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523-528. (Pubitemid 351397977)
11. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522. (Pubitemid 35397061)
12. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, and Bertilsson L (2008) Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 64:275-282.
13. Guengerich FP, Hanna IH, Martin MV, and Gillam EM (2003) Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 42:1245-1253. (Pubitemid 36184065)
14. Hayhurst GP, Harlow J, Chowdry J, Gross E, Hilton E, Lennard MS, Tucker GT, and Ellis SW (2001) Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem J 355:373-379. (Pubitemid 32397796)
15. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304. (Pubitemid 46174829)
16. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844. (Pubitemid 40686638)
17. Johnson JA and Burlew BS (1996) Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 24:350-355. (Pubitemid 26087089)
18. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727. (Pubitemid 29520596)
19. Kirch W, Spahn H, Köhler H, Ohnhaus EE, and Mutschler E (1982) Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr 60:1401-1407. (Pubitemid 13241034)
20. Kronbach T (1991) Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol 206:509-517.
21. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
22. Kurtz DL, Bergstrom RF, Goldberg MJ, and Cerimele BJ (1997) The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 62:145-156. (Pubitemid 27373462)
23. Leemann TD, Devi KP, and Dayer P (1993) Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.Eur J Clin Pharmacol 45:65-71. (Pubitemid 23225959)
24. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospholipidon the inhibition of cytochrome P4502D6: implications for relating in vitro inhibitiondata to in vivo drug interactions. Drug Metab Dispos 31:606-611. (Pubitemid 36444170)
25. McGinnity DF, Waters NJ, Tucker J, and Riley RJ (2008) Integrated in vitro analysis for the invivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab Dispos36:1126-1134. (Pubitemid 351717471)
26. Mutschler E, Spahn H, and Kirch W (1984) The interaction between H2-receptor antagonists andβ-adrenoceptor blockers. Br J Clin Pharmacol 17 (Suppl 1):51S-57S. (Pubitemid 14052239)
27. Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, Uchida E, andTanaka H (2007) Effect of cinacalcet hydrochloride, a new calcimimetic agent, on thepharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol47:1311-1319. (Pubitemid 47459660)
28. Nichols AI, Fatato P, Shenouda M, Paul J, Isler JA, Pedersen RD, Jiang Q, Ahmed S, andPatroneva A (2009) The effects of desvenlafaxine and paroxetine on the pharmacokinetics ofthe cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 49:219-228.
29. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, and Wolf CR(2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificityand product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027. (Pubitemid 36801135)
30. Patroneva A, Connolly SM, Fatato P, Pedersen R, Jiang Q, Paul J, Guico-Pabia C, Isler JA,Burczynski ME, and Nichols AI (2008) An assessment of drug-drug interactions: the effect ofdesvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine inhealthy subjects. Drug Metab Dispos 36:2484-2491.
31. Porubsky PR, Meneely KM, and Scott EE (2008) Structures of human cytochrome P-450 2E1.Insights into the binding of inhibitors and both small molecular weight and fatty acidsubstrates. J Biol Chem 283:33698-33707.
32. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-DavisA, Desta Z, and Burt T (2007) Comparison of duloxetine, escitalopram, and sertraline effectson cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 27:28-34. (Pubitemid 46105760)
33. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolismin human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
34. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, odi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622. (Pubitemid 43847532)
35. Steiner E and Spina E (1987) Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 42:278-282. (Pubitemid 17155732)
36. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
37. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, and Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49:234-240.
38. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, and Shader RI (1998) Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 87:1184-1189. (Pubitemid 28455606)
39. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
40. Wójcikowski J, Maurel P, and Daniel WA (2006) Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 34:471-476. (Pubitemid 43290906)
41. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, et al. (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75-82. (Pubitemid 351861487)
42. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319. (Pubitemid 35397032)
43. Zhou SF (2009a) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689-723.
44. Zhou SF (2009b) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 48:761-804.